| Oct 7 |
Update: Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint
|
| Oct 7 |
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
|
| Oct 7 |
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
|
| Oct 7 |
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
|
| Oct 7 |
Scholar Rock scores with ‘surprise’ success in SMA drug study
|
| Oct 7 |
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
|
| Sep 27 |
Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now
|
| Sep 10 |
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
|
| Sep 5 |
Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now
|
| Sep 4 |
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
|
